RxDoctor Payments Data

John Scheland, DPM

Podiatrist · Clarks Summit, PANPI 1780640128

Payments from drug & device makers

What this record shows

This record is dominated by other: $49,100 of the $54,122 with a category attached, or 90.7%. Smith+Nephew accounts for 92.0% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2023 at $50,076 and has fallen 98.9% since, to $551 in 2025. Among podiatrist clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$54,122in general payments, 2019–2025

Across 168 payments — averaging $322.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$50K
  • Stryker$2K
  • Paratek Pharmaceuticals, Inc.$914
  • Kowa Pharmaceuticals America, Inc.$471
  • Paragon 28, Inc.$426
  • Organogenesis Inc.$177
  • plus $516 from 13 others

What the payments were for

  • Food & beverage$4,9229%
  • Education$1000%
  • Other$49,10091%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$54,122 in reported general payments places this provider in the 95th percentile of 445 podiatrist providers in Pennsylvania.

See all podiatrist providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$1,008,414
Medicare patients
257
Services billed
1,702

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban11$6,338
Terbinafine Hcl19$267
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip14$227
Diclofenac Sodium11$224
Tramadol Hcl18$221
Gabapentin22$200
Amitriptyline Hcl22$183
Cephalexin39$180
Methylprednisolone21$160
Meloxicam28$149
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen38$127

Paid to pharmacies, not to this prescriber.

Other podiatrist in Clarks Summit

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →